Monte Rosa Therapeutics, Inc. Common Stock
Veridion Score
Composite trend over time
Why is GLUE moving today?
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for GLUE.
GLUE insider activity
Monte Rosa Therapeutics, Inc. Common Stock
No multi-insider buying cluster in the last 90 days
Mixed: Not disclosed across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
The current Form 4 feed did not return value-bearing open-market rows for GLUE.
GLUE contract awards, year to date.
Public federal awards linked to this ticker.
GLUE lobbying filings, year to date.
Registered lobbying filings matched to Monte Rosa Therapeutics, Inc. Common Stock.